pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,072 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1857Endpoints1442Fierce Biotech761BioSpace748BioPharma Dive544raps249onclive165fda recalls
therapy area
allOncology12834Rare Disease3326Immunology2986Cardiology2845Hematology2286Pulmonology2234Vaccines
  • GSK receives FDA accelerated approval for neladalkib (Nelkarmi) in ALK-positive lung cancer, second win from Nuvalent deal
    GSK announced that the FDA has granted accelerated approval to its tyrosine kinase inhibitor neladalkib, to be sold under the brand name Nelkarmi, for patients with ALK‑positive non‑small cell lung…
    BioSpace · 1h agoApprovalPositive↗ source
  • AI bio startup Boltz secures $110 million Series A as AI drug design platform usage surges
    Boltz, an artificial‑intelligence driven biotech startup, announced a $110 million Series A financing round less than a year after emerging from stealth with an initial $28 million investment. The…
    Endpoints · 2h agoDealPositive↗ source
← prev
page 1 of 203
next →
118
fda medwatch114
globenewswire health73
fda press61
1844
Psychiatry & CNS1229
Ophthalmology1129
Endocrinology & Metabolism806
Pain789
Nephrology782
  • FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failure
    The U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…
    BioSpace · 3h agoRegulatoryNegative↗ source
  • Pfizer CEO warns China will be major biotech competitor by 2030 and urges AI-driven cost cuts
    At the Jefferies Global Healthcare Conference in London, Pfizer chief Albert Bourla said China is rapidly building its biotech sector and could become the company's biggest rival by 2030, surpassin…
    BioSpace · 53m agoNeutral↗ source
  • FDA rejects Summit Therapeutics' ivonescimab, citing trial design and safety concerns
    Summit Therapeutics received a Complete Response Letter from the FDA rejecting its application for ivonescimab, a PD-1xVEGF combination intended for EGFR-mutated non-small cell lung cancer. The ag…
    BioSpace · 1h agoRegulatoryNegative↗ source
  • Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater China
    Pfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…
    Endpoints · 2h agoDealPositive↗ source
  • Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchase
    Merck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…
    Endpoints · 2h agoDealNegative↗ source
  • Acquisitions can tie big pharma to existing biotech partners, creating co-parenting challenges
    Acquiring a biotech that already works with another large pharmaceutical firm can bring extra obligations beyond the technology and pipeline being bought. The report highlights Merck KGaA’s planne…
    BioSpace · 9h agoDealNeutral↗ source
  • Biogen's low-dose tau drug shows greater slowing of Alzheimer’s progression after two years
    Biogen reported new data on its experimental tau-reducing therapy diranersen, showing that the lowest dose continued to slow Alzheimer’s disease progression after nearly two years of treatment. Th…
    Endpoints · 13h agoPositive readoutPositive↗ source
  • White House withdraws Trump nominee Heidi Overton from FDA commissioner consideration amid Senate doubts
    The White House announced it has pulled Heidi Overton, the Trump administration’s nominee to serve as commissioner of the Food and Drug Administration. Overton’s nomination had been moving through…
    Endpoints · 14h agoRegulatoryNegative↗ source
  • Debate Over Medical School Structure Emerges as U.S. Loses Measles Elimination Status
    A discussion is unfolding about whether the traditional four‑year medical school model should be broken into separate components. The idea was voiced by a medical student who asked if every part of…
    STAT · 1h agoNegative↗ source
  • Loss of Senate Appropriations Chair Susan Collins could weaken scientists’ fight against new research oversight rule
    Senator Susan Collins, the Republican chair of the Senate Appropriations Committee, was defeated in her re‑election, ending her role as the most prominent GOP ally for science advocates. Scientist…
    STAT · 5h agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton’s FDA commissioner nomination amid Senate opposition
    The White House pulled the nomination of Heidi Overton for FDA commissioner just hours before the Senate Health, Education, Labor, and Pensions (HELP) committee was set to vote. Overton, who serve…
    BioSpace · 12h agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton's nomination to lead the FDA amid Senate Republican concerns
    The White House announced it is withdrawing its nominee, Heidi Overton, for FDA commissioner. Overton, a preventive care physician who previously served in the Trump administration, faced resistan…
    STAT · 13h agoRegulatoryNegative↗ source
  • BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026
    BioSpace introduced a new IPO dashboard that monitors U.S. biotech companies that went public in 2026. The tool will be refreshed weekly with the latest closing prices and will add any newly liste…
    BioSpace · 2h agoNeutral↗ source
  • Opinion calls for impeachment of Health Secretary Robert F. Kennedy Jr. over anti‑vaccine stance
    Professor Paul Knoepfler, a cell‑biology faculty member at UC Davis, argues that the post‑midterm political climate creates a window to remove Health and Human Services Secretary Robert F. Kennedy…
    STAT · 5h agoNegative↗ source
  • Opinion argues that traditional four-year medical schools may be outdated for pre-clerkship training
    Alex Serafini, a fourth‑year medical student at Icahn School of Medicine, contributes to a new First Opinion series that questions the structure of modern medical education. He notes that over the…
    STAT · 5h agoNeutral↗ source
  • Why comparing every new employer to your last one can hurt your influence
    Executive coach Angela Justice advises professionals not to treat their former workplace as the standard for every new job. She says the habit can cloud judgment and reduce a person's influence. W…
    BioSpace · 9h agoNeutral↗ source
  • FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancers
    The U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…
    BioPharma Dive · 21h agoApprovalPositive↗ source
  • Isomorphic Labs lands record $5 billion Series C, marking biggest private biotech raise ever
    Isomorphic Labs, a Google-backed biotech company, announced a $5 billion Series C financing round. The round, completed just six months after a $2.1 billion raise, is the largest private capital r…
    Endpoints · 22h agoDealPositive↗ source
  • Isomorphic Labs raises record $5 billion in Series C, doubling its May funding
    Isomorphic Labs, an AI-driven drug design company, announced a $5 billion Series C financing, the largest private biotech raise ever and more than double its $2.1 billion Series B from May. The ro…
    BioSpace · 22h agoDealPositive↗ source
  • Vertex awaits FDA decision on povetacicept for IgA nephropathy, analysts expect approval
    Vertex Pharmaceuticals is awaiting an FDA ruling this month on its investigational drug povetacicept, being evaluated for the treatment of IgA nephropathy. Analysts, including Myles Minter of Will…
    BioSpace · 22h agoRegulatoryPositive↗ source
  • Sellas cancer vaccine cuts death risk by 41% in late-stage AML trial
    Sellas Life Sciences announced results from its Phase 3 REGAL trial evaluating an off‑the‑shelf cancer vaccine in patients with acute myeloid leukemia (AML). The study enrolled 126 individuals who…
    BioSpace · 1d agoPositive readoutPositive↗ source
  • Roche secures FDA approval for giredestrant, its first SERD for advanced breast cancer
    Roche announced that its experimental breast cancer drug giredestrant received FDA approval for treatment of patients with late‑stage disease. The approval places Roche into the selective estrogen…
    Endpoints · 1d agoApprovalPositive↗ source
  • GSK receives accelerated FDA approval for oral lung cancer drug neladalkib
    GSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
    Endpoints · 18h agoApprovalPositive↗ source